30 Best Stocks to Buy Right Now for a Home-Run Swing

If you've got some money socked away for a truly speculative, high-upside swing, here are 30 of Wall Street's most bullish calls.

A baseball player hitting a no-doubt home run in a giant stadium
(Image credit: Getty Images)

Aggressive investors scouting out the best stocks to buy right now would do well to keep an eye on the research community.

That might sound like pretty commonsensical advice, but it's not typically the case. You see, while Wall Street's analysts are an optimistic bunch, they're not exactly an exuberant bunch.

On the one hand, Sell calls by the Street are indeed quite rare – so much so that even stocks that are heavy in mere Hold calls should get a wary eye.

Subscribe to Kiplinger’s Personal Finance

Be a smarter, better informed investor.

Save up to 74%
https://cdn.mos.cms.futurecdn.net/flexiimages/xrd7fjmf8g1657008683.png

Sign up for Kiplinger’s Free E-Newsletters

Profit and prosper with the best of Kiplinger’s expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.

Profit and prosper with the best of Kiplinger’s expert advice - straight to your e-mail.

Sign up

But analysts aren't exactly known for making bombastic calls, either. Investors looking to make a truly speculative high-risk, high-reward bet are much more likely to find predictions of doublers from Reddit and Twitter than respected research firms.

Consider this: Among analysts surveyed by S&P Global Market Intelligence, the average 12-month upside for an S&P 500 stock is a mere 11.9% – just a couple of points better than the average 9%-10% you can expect out of the index in an average year.

Admittedly, the S&P 500's best stocks to buy right now have quite a bit more upside in them – a pair, Enphase Energy (ENPH (opens in new tab)) and Penn National Gaming (PENN (opens in new tab)), are predicted to scoot about 70% higher over the next 12 months or so. But if you're willing to venture a little farther afield, you can find a few stocks that Wall Street is so collectively bullish on, the average upside expectation for this time next year sits at least 100% higher than current levels.

The 30 Best Stocks to Buy Right Now for Speculative Investors

We screened the Russell 3000 for stocks that Wall Street analysts are exceedingly bullish on. Here's what we were looking for:

  • Stocks covered by at least 10 analysts. The presence of just one or two covering analysts can make for some pretty easily skewed results. However, a crowd of at least 10 Wall Street pros ensures that even a wildly optimistic prediction won't throw off the average by too much.
  • Stocks with solid Buy ratings. S&P scores analysts' stock calls on a five-point scale, where 1.0 equals a Strong Buy and 5.0 is a Strong Sell. Anything below 2.5 translates into a Buy call, and anything below 1.5 is a Strong Buy call. We looked for companies with scores of 2.0 or below, meaning they're either high-conviction Buy calls or Strong Buy calls.
  • Stocks with implied upside of at least 100%. To sniff out Wall Street's most optimistic calls, the average 12-month price target must translate into a minimum of 100% upside for shares.

The result? A cool 30 stocks that the pros think will jump anywhere between 101% to a whopping 541% in just the next year alone.

Be forewarned, however, that higher implied rewards also imply higher risk. The stocks listed here tend to carry greater levels of volatility, and therefore greater potential for loss.

The full table is below, but first, we'll point out one trait that shouldn't surprise anyone: a heaping helping of biotech stocks. About two-thirds of these stocks – including nine of the top 10 – come from the biotechnology space, where a single positive drug-trial result can vastly change a company's trajectory and generate quick, massive returns.

Homology Medicines (FIXX (opens in new tab), $3.49), for instance, is "an emerging contender in the field of Adeno-associated virus-based gene therapy," say Oppenheimer analysts, who rate the stock at Outperform (equivalent of Buy) and believe it can hit $22 per share – more than six times current prices – over the next 12 months. And Raymond James has an Outperform rating and $13 price target on Viking Therapeutics (VKTX (opens in new tab), $4.20), calling its VK2809 "potentially the best oral [non-alcoholic Steatohepatitis] drug in development."

If you're looking for more traditional picks, consider Kiplinger's 22 best stocks to buy for 2022. But if you want to swing for the fences, here are Wall Street's 30 best moonshots:

List of top stocks to buy

(Image credit: S&P Global Market Intelligence)
Kyle Woodley
Senior Investing Editor, Kiplinger.com

Kyle is senior investing editor for Kiplinger.com. As a writer and columnist, he also specializes in exchange-traded funds. He joined Kiplinger in September 2017 after spending six years at InvestorPlace.com, where he managed the editorial staff. His work has appeared in several outlets, including U.S. News & World Report and MSN Money, he has appeared as a guest on Fox Business Network and Money Radio, and he has been quoted in MarketWatch, Vice and Univision, among other outlets. He is a proud graduate of The Ohio State University, where he earned a BA in journalism.